{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-066250","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.349127+00:00","generated_at":"2026-06-07T21:05:44.652483+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Erasca prioritizes pipeline, extends cash runway to H1 2026; FDA/EMA agree on Phase 3 naporafenib trial","bullets":["FDA/EMA endorsed SEACRAFT-2 Phase 3 design for naporafenib+trametinib in NRASm melanoma; dual primary endpoints PFS and OS.","Phase 1 data for ERAS-801 in rGBM: MTD 240 mg QD, safe, PK above 90% tumor growth inhibition; expansion cohorts enrolling.","Deprioritized FLAGSHP-1 (ERAS-601+cetuximab), ERAS-5, ERAS-10; cash runway extended from H2 2025 to H1 2026.","Key upcoming milestones: naporafenib Phase 1b data in RAS Q61X tumors (2H 2024), ERAS-007 combo data in BRAFm CRC (H2 2023–H1 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-066250","json":"https://secwatch.observer/filing/0000950170-23-066250.json","markdown":"https://secwatch.observer/filing/0000950170-23-066250.md","text":"https://secwatch.observer/filing/0000950170-23-066250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023066250/0000950170-23-066250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023066250/eras-20231128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:05:44.652483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}